The U.S. Food and Drug Administration Tuesday announced that it has placed a clinical hold on Gilead Sciences' (GILD) investigational HIV trials combining GS-1720 and GS-4182.
This action follows identification of a safety signal declines in CD4+ T-cell and absolute lymphocyte counts—in some participants receiving the combo. Trial investigators have been notified. Neither agent is approved anywhere, and Gilead is working with regulators to address the findings and determine a path forward.
This hold affects two Phase 2/3 WONDERS studies and three Phase 1 trials but does not impact Gilead's other long-acting oral or injectable HIV regimens under clinical or preclinical evaluation. Patient safety remains Gilead's top priority.
GILD is currently trading at $110.72, down $2.28 or 2.02 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.